FDA Approves Centanafadine for ADHD in Children, Adolescents, and Adults
The FDA has approved Otsuka's Simtriyo (centanafadine), the first new-class ADHD medication for pediatric and adult patients in decades.
Velocity timeline
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
The FDA has granted approval for Simtriyo (centanafadine), a first-in-class triple reuptake inhibitor developed by Otsuka. The medication is indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients aged 6 years and older.
Coverage from Medical Daily and FirstWord Pharma emphasizes that this represents the first new drug class for ADHD in decades. Psychiatric Times and mykxlg.com highlight the clinical path leading to the FDA review and the drug's specific classification as a triple reuptake inhibitor.
Future developments involve the rollout of Simtriyo to the specified patient populations, including children, adolescents, and adults.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated just now.
Quick answers
Who developed the medication?
The drug was developed by Otsuka.
Who is eligible to use Simtriyo?
It is approved for adults and pediatric patients aged 6 years and older.
What makes this drug different from previous ADHD medications?
According to coverage, it is a first-in-class triple reuptake inhibitor and the first new-class ADHD drug for children and adults in decades.
Coverage (5)
- Centanafadine's Route to FDA Review: A Clinical Path of the ADHD Medication Psychiatric Times · 2d ago broke it first
- Otsuka Receives FDA Approval for First-in-Class SIMTRIYO® (centanafadine) for the Treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in Adults and Pediatric Patients Aged 6 Years and Older mykxlg.com · 2d ago
- FDA Rules Today on First New-Class ADHD Drug for Kids and Adults in Decades Medical Daily · 2d ago
- Otsuka's triple reuptake inhibitor Simtriyo wins FDA OK for ADHD FirstWord Pharma · 2d ago
- FDA Approves Centanafadine for ADHD in Children, Adolescents, and Adults Psychiatric Times · 2d ago broke it first
People, places & organizations
Topics
From around our network
Related trends
Brooklyn Roasting Company recalls cold brew sold in New York and New Jersey over botulism risk
7 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.
We’re beating heart disease
The US FDA has approved enlicitide, the first oral pill designed to replace injections for lowering high cholesterol.
FDA recalls 180,000 cans of soup sold at Walmart - the-sun.com
8 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.
Salmonella outbreak tied to eggs has sickened 98 people in 17 states since November, FDA says
The FDA and CDC are tracking a Salmonella outbreak linked to shell eggs that has sickened 98 people across 17 states since November.
Trump's former top food official: Cyclospora outbreak ‘approaching catastrophic’ level
Former FDA Commissioner Dr. Scott Gottlieb warns that the federal response to a multi-state Cyclospora outbreak is approaching a 'catastrophic' level.
US FDA approves over-the-counter Tylenol combination pill for pain relief
5 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.